Martín Irigoyen Arredondo

Dr. Martín Irigoyen Arredondo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in Heliyon
Verified
Journal Article
Open access
FBFernando Bergez-Hernandez
Fernando Bergez-Hernandez
MAMartín Irigoyen Arredondo
Martín Irigoyen Arredondo
AMAlejandra Paola Martinez-Camberos
Alejandra Paola Martinez-Camberos
The Phosphatase and Tensin Homolog gene (PTEN) is pivotal in regulating diverse cellular processes, including growth, differentiation, proliferation, and cell survival, mainly by modulating the PI3K/AKT/mTOR pathway. Alterations in the expression of the PTEN gene have been associated with epigenetic mechanisms, particularly the regulation by small non-coding RNAs, such as miRNAs. Modifications in the expression levels of miRNAs that control PTEN have been shown to lead to its underexpression. This underexpression, in turn, impacts the PI3K/AKT/mTOR pathway, thereby influencing crucial mechanisms like proliferation and apoptosis, playing an important role in the initiation and progression of prostate cancer (PCa). Thus, we aimed to systematically reviewed available information concerning the regulation of PTEN mediated by miRNA in PCa. Electronic databases were searched to identify studies assessing PTEN regulation via PCa miRNAs, the search included combination of the words microRNAs, PTEN and prostatic neoplasms. The quality assessment of the articles included was carried out using an adapted version of SYRCLE and CASP tool. We included 39 articles that measured the relative gene expression of miRNAs in PCa and their relationship with PTEN regulation. A total of 42 miRNAs were reported involved in the development and progression of PCa via PTEN dysregulation (34 miRNAs up-regulated and eight miRNAs down-regulated). Sixteen miRNAs were shown as the principal regulators for genetic interactions leading to carcinogenesis, being the miR-21 the most reported in PCa associated with PTEN down-regulation. We showed the silencing of PTEN could be promoted by a loop between miR-200b and DNMT1 or by direct targeting of PTEN by microRNAs, leading to the constitutive activation of PI3K/AKT/mTOR and interactions with intermediary genes support apoptosis inhibition, proliferation, invasion, and metastasis in PCa. According to our review, dysregulation of PTEN mediated mainly by miR-21, -20a, -20b, -93, -106a, and -106b up-regulation has a central role in PCa development and could be potential biomarkers for diagnosis, prognostic, and therapeutic targets.

1 January 2026 in Biomedical and Biotechnology Research Journal
Verified
Journal Article
Open access
FBFernando Antonio Bergez-Hernández
Fernando Antonio Bergez-Hernández
AMAlejandra Paola Martínez-Camberos
Alejandra Paola Martínez-Camberos
MAMartín Irigoyen Arredondo
Martín Irigoyen Arredondo
Background: Prostate cancer (PCa) remains a major clinical challenge due to the limited ability of current diagnostic tools to distinguish indolent from aggressive tumors. MicroRNAs (miRNAs) have emerged as promising biomarkers given their stability, tissue specificity, and regulatory roles in carcinogenesis. This study analyzed miRNA expression and clinical data from The Cancer Genome Atlas–Prostate Adenocarcinoma (TCGA-PRAD) to identify differentially expressed miRNAs and evaluate their association with tumor aggressiveness. Methods: miRNA expression profiles and clinical variables from TCGA-PRAD were examined. A total of 550 samples (498 tumors, 52 adjacent normal) and 1,881 miRNAs were analyzed using the differential expression sequencing 2 workflow. Differential expression was assessed using adjusted significance thresholds. Highly deregulated miRNAs were identified based on log2 fold change ≥2 and false discovery rate (FDR) <0.01. Associations with the Gleason score were evaluated using Spearman correlation with multiple testing correction. Results: We identified 137 significantly deregulated miRNAs (FDR < 0.05), with no global trend toward over-or underexpression. Applying stringent filters yielded 24 miRNAs with high-magnitude changes. Correlation analysis revealed 25 miRNAs significantly associated with the Gleason score. The miR-449a, miR-184, and miR-891a showed both strong deregulation and significant correlation with aggressiveness. miR-449a exhibited the greatest tumor overexpression, whereas miR-184 and miR-891a displayed expression patterns consistent with pathways previously linked to proliferation, invasion, and tumor progression. Conclusion: miR-449a, miR-184, and miR-891a emerge as strong candidates for PCa progression biomarkers. Their combined deregulation and association with the Gleason score support their potential as prognostic indicators and therapeutic targets. Validation in independent cohorts and functional studies will be essential to confirm their clinical applicability.

9 April 2026 in Epigenomes
Verified
Journal Article
Open access
PDF file
FBFernando Bergez-Hernandez
Fernando Bergez-Hernandez
MAMartín Irigoyen Arredondo
Martín Irigoyen Arredondo
LFLizeth Carolina Flores-Méndez
Lizeth Carolina Flores-Méndez
AMAlejandra Paola Martinez-Camberos
Alejandra Paola Martinez-Camberos
Background: Aging is the strongest risk factor for prostate cancer (PCa). It is accompanied by progressive epigenomic divergence, known as epigenetic drift, particularly affecting DNA methylation at regulatory regions. However, the extent to which age-associated promoter methylation contributes to coordinated microRNA (miRNA) expression changes in PCa remains incompletely characterized. Methods: We conducted an integrative in silico analysis of 449 primary tumors from the TCGA-PRAD cohort. Age was modeled as a continuous variable. Age-related miRNA expression changes were estimated from miRNA-seq data using DESeq2. Promoter DNA methylation changes (±2 kb from transcription start sites) were assessed using Illumina 450K arrays and linear regression. MiRNAs showing significant age-associated alterations at both expression and methylation levels were classified as concordant or discordant based on directionality and prioritized using an effect size-based concordance score. We analyzed experimentally validated targets of prioritized miRNAs through functional enrichment and network-based approaches to identify convergent regulatory pathways. Results: Initially, we identified 105 age-associated miRNAs. After filtering, 65 candidates remained. Of these, we found 37 miRNAs with significant age-associated changes at both layers, including 20 concordant and 17 discordant miRNAs. These comprised well-characterized cancer-associated miRNAs and lesser-studied candidates enriched in CpG-rich regulatory regions. Network analyses revealed a limited set of genes under convergent regulation by multiple age-associated miRNAs. These implicated pathways are related to cell cycle control, apoptosis, stress response, and epigenetic regulation. Conclusions: Our findings support a model in which age-dependent promoter methylation drift contributes to coordinated miRNA deregulation in PCa. This convergence highlights biologically plausible miRNA biomarkers and age-sensitive epigenetic circuits relevant to prostate carcinogenesis.

Verified
Journal Article
Open access
PDF file
FBFernando Bergez-Hernandez
Fernando Bergez-Hernandez
AMAlejandra Paola Martinez-Camberos
Alejandra Paola Martinez-Camberos
JRJosé Geovanni Romero-Quintana
José Geovanni Romero-Quintana
JUJesus Ricardo Parra Unda
Jesus Ricardo Parra Unda
LGLennin Isaac Garrido-Palazuelos
Lennin Isaac Garrido-Palazuelos
MAMartín Irigoyen Arredondo
Martín Irigoyen Arredondo
Prostate cancer (PCa) is a highly heterogeneous disease, and the molecular features underlying differences in tumor aggressiveness remain incompletely understood. This study aimed to characterize the molecular differences between young aggressive (YA) and old indolence-associated (OI) prostate tumors using an integrative multi-omics approach. RNA sequencing, copy number alteration (CNA), and clinical data from The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) cohort were analyzed. YA tumors (age ≤ 58 years, Gleason score ≥ 8; n = 30) were compared with OI tumors (age ≥ 67 years, Gleason score ≤ 7; n = 41). YA tumors exhibited higher FGA and a greater nominal frequency of homozygous PTEN deletion, consistent with increased genomic instability. Transcriptomic analysis identified 1083 differentially expressed genes, whereas integrative RNA–CNA analysis prioritized 40 exploratory concordant genes, 35 of which showed copy-number loss-associated downregulation. Sensitivity analyses showed that 8 of 40 genes retained both the predefined FDR and effect-size criteria after tumor-purity adjustment, whereas only one gene retained both criteria after additional adjustment for pT and N. Functional enrichment and network analyses identified metabolic and homeostatic programs and a central interaction module within the original prioritized gene set. These findings provide exploratory hypotheses regarding molecular differences between the two predefined extreme phenotypes.

Verified
Journal Article
Open access
PDF file
KHKarla Lizbeth Morales Hernández
Karla Lizbeth Morales Hernández
NMNoemí García Magallanes
Noemí García Magallanes
MAMarco Antonio Alvarez-Arrazola
Marco Antonio Alvarez-Arrazola
FOFRED LUQUE ORTEGA
FRED LUQUE ORTEGA
MAMartín Irigoyen Arredondo
Martín Irigoyen Arredondo
EAEliakym Arámbula
Eliakym Arámbula
Prostate cancer (PCa) represents a significant cause of cancer-associated mortality in the male population worldwide and constitutes a multifactorial disease influenced by genetic and epigenetic factors. Deregulation of genes such as AR and PTEN, as well as alteration in the expression of microRNAs (miRNAs), including miR-145-5p and miR-148b-3p, has been observed in this pathology. This study aimed to explore the correlation between the expression of miR-145-5p, miR-148b-3p, and PTEN in prostate tissue, providing initial insight into their potential interaction in cancer biology. We analyzed 71 samples, comprising 41 from patients with confirmed prostate cancer (PCa group) and 30 from patients with benign prostatic disease (BPD group). Our findings demonstrated a statistically significant association between both miRNAs and the PTEN gene, specifically between miR-148b-3p and PTEN (p = 0.00001) and between miR-145-5p and PTEN (p = 0.0078). These findings support the hypothesis that reduced levels of these miRNAs may be linked to PTEN regulation in prostate pathologies and underscore their potential relevance in PCa biology.

22 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMartín Irigoyen Arredondo
Martín Irigoyen Arredondo
AMAlejandra Paola Martinez-Camberos
Alejandra Paola Martinez-Camberos
LFLizeth C. Flores-Méndez
Lizeth C. Flores-Méndez
CHCrisantema Hernández
Crisantema Hernández
JRJosé Geovanni Romero-Quintana
José Geovanni Romero-Quintana
FBFernando Bergez-Hernandez
Fernando Bergez-Hernandez
Background/Objectives: Catalase (CAT) plays a pivotal role in cellular redox homeostasis by catalyzing the decomposition of hydrogen peroxide, thereby mitigating oxidative damage. Impaired CAT function has been linked to chronic inflammation, deregulated cell proliferation, and oncogenesis. While numerous CAT variants have been reported, their functional relevance in prostate cancer (PCa) remains unclear. This study investi-gated CAT genetic variants, enzymatic activity, and potential pathogenic significance in PCa. Methods: Peripheral blood samples from 17 patients with prostate cancer (PCa) and 17 patients with benign prostatic hyperplasia (BPH) were processed for genomic DNA extraction and quantification. Reported missense variants were screened using pub-lic genomic databases. Pathogenicity was predicted with SNPs&GO, PolyPhen-2, and I-Mutant 2.0. Protein modeling was performed with UCSF Chimera, and structural quality was assessed via Ramachandran plots. Two selected variants (L299F, A333T) were geno-typed using the rhAmp™ SNP assay. Serum CAT activity was quantified spectrophoto-metrically (240 nm) following Aebi’s protocol. Results: CAT activity was significantly re-duced in PCa compared to BPH (1.44 ± 0.24 vs. 1.91 ± 0.25 U/mg protein, p = 0.033), with no association to age, PSA levels, or comorbidities. In silico predictions identified variants K177T, G216V, and L351P as potentially deleterious, while N452S appeared benign. Gen-otyping revealed that all participants were wild-type homozygous for L299F and A333T. Conclusions: PCa is characterized by diminished CAT activity independent of the inves-tigated variants, suggesting an alternative regulatory mechanism, such as epigenetic reg-ulation or post-translational modifications, may drive CAT downregulation. These find-ings support further investigation into CAT as a potential biomarker and therapeutic tar-get in oxidative stress–mediated prostate carcinogenesis.